All tracked trials

Phase 2 and Phase 3 cancer trials run by companies on the Nasdaq or New York Stock Exchange.

1,669 trials · most recently edited first

LLYLoxo Oncology, Inc.
10Calm
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
FinishedPhase 1/2803 patientsMain results: Jan 27, 2025
BOLTBolt Biotherapeutics, Inc.
6Calm
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
Signing up patientsPhase 1/2122 patientsMain results: May 2027
GSKGlaxoSmithKline
0Calm
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Signing up patientsPhase 3892 patientsMain results: Mar 19, 2029
BMYBristol-Myers Squibb
10Calm
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
FinishedPhase 2102 patientsMain results: Nov 12, 2025
ARGXargenx
0Calm
Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis
FinishedPhase 3184 patientsMain results: Dec 31, 2024
BMYBristol-Myers Squibb
10Calm
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Running, no new patientsPhase 3437 patientsMain results: Mar 11, 2027
NVCRNovoCure Ltd.
2Calm
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
FinishedPhase 3571 patientsMain results: Oct 16, 2024
BMYBristol-Myers Squibb
10Calm
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
FinishedPhase 1/2219 patientsMain results: Aug 31, 2024
INCYIncyte Corporation
0Calm
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
Running, no new patientsPhase 1/253 patientsMain results: Jul 17, 2024
JNJJanssen Research & Development, LLC
15Calm
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Running, no new patientsPhase 1/2228 patientsMain results: Mar 18, 2025
BLRXBioLineRx, Ltd.
0Calm
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
Running, no new patientsPhase 3180 patientsMain results: Dec 22, 2020
BFRIBiofrontera Inc.
0Calm
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).
Running, no new patientsPhase 3187 patientsMain results: Mar 19, 2024
NUVBNuvation Bio Inc.
0Calm
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Running, no new patientsPhase 1/2466 patientsMain results: Mar 2027
IBRXImmunityBio, Inc.
0Calm
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Running, no new patientsPhase 240 patientsMain results: Aug 31, 2029
NVSNovartis Pharmaceuticals
5Calm
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC
FinishedPhase 240 patientsMain results: Nov 7, 2024
INDPIndaptus Therapeutics, Inc
0Calm
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Running, no new patientsPhase 1/2120 patientsMain results: Jun 30, 2027
NVSNovartis Pharmaceuticals
15Calm
Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy
FinishedPhase 3718 patientsMain results: May 28, 2025
MRKMerck Sharp & Dohme LLC
5Calm
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Running, no new patientsPhase 1/2230 patientsMain results: Apr 23, 2027
LLYPOINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
0Calm
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
Running, no new patientsPhase 3455 patientsMain results: Nov 1, 2023
MAIAMaia Biotechnology
0Calm
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Signing up patientsPhase 3300 patientsMain results: Jul 31, 2027
VSTMVerastem, Inc.
12Calm
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
Running, no new patientsPhase 1/2153 patientsMain results: Jun 2026
TYRATyra Biosciences, Inc
0Calm
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
Running, no new patientsPhase 1/2310 patientsMain results: Nov 2026
AMGNAmgen
2Calm
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
Running, no new patientsPhase 3633 patientsMain results: Jan 25, 2028
ABBVAbbVie
1Calm
Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers
FinishedPhase 279 patientsMain results: Dec 12, 2024
ABBVAbbVie
11Calm
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
Running, no new patientsPhase 3330 patientsMain results: Jan 29, 2025